Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonilla-Abadía, Fabio, Coronel Restrepo, Nicolás, Tobón, Gabriel J., Echeverri, Andrés F., Muñoz-Buitrón, Evelyn, Castro, Andres Mauricio, Bejarano, Mercedes Andrade, Cañas, Carlos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914290/
https://www.ncbi.nlm.nih.gov/pubmed/24527208
http://dx.doi.org/10.1155/2014/731806
Descripción
Sumario:Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment.

Ejemplares similares